Showing 121,141 - 121,160 results of 125,008 for search '(( 5 ((a decrease) OR (nn decrease)) ) OR ( a ((mean decrease) OR (point decrease)) ))', query time: 1.15s Refine Results
  1. 121141

    Data_Sheet_6_Changes in Metabolism and Proteostasis Drive Aging Phenotype in Aplysia californica Sensory Neurons.PDF by Nicholas S. Kron (9377615)

    Published 2020
    “…The marine mollusk Aplysia californica (Aplysia) is a premier model for the nervous system uniquely suited to investigation of neuronal aging due to uniquely identifiable neurons and molecular techniques available in this model. …”
  2. 121142

    Table_4_Changes in Metabolism and Proteostasis Drive Aging Phenotype in Aplysia californica Sensory Neurons.xlsx by Nicholas S. Kron (9377615)

    Published 2020
    “…The marine mollusk Aplysia californica (Aplysia) is a premier model for the nervous system uniquely suited to investigation of neuronal aging due to uniquely identifiable neurons and molecular techniques available in this model. …”
  3. 121143

    Table_7_Changes in Metabolism and Proteostasis Drive Aging Phenotype in Aplysia californica Sensory Neurons.xlsx by Nicholas S. Kron (9377615)

    Published 2020
    “…The marine mollusk Aplysia californica (Aplysia) is a premier model for the nervous system uniquely suited to investigation of neuronal aging due to uniquely identifiable neurons and molecular techniques available in this model. …”
  4. 121144

    Data_Sheet_1_Changes in Metabolism and Proteostasis Drive Aging Phenotype in Aplysia californica Sensory Neurons.PDF by Nicholas S. Kron (9377615)

    Published 2020
    “…The marine mollusk Aplysia californica (Aplysia) is a premier model for the nervous system uniquely suited to investigation of neuronal aging due to uniquely identifiable neurons and molecular techniques available in this model. …”
  5. 121145

    Data_Sheet_3_Changes in Metabolism and Proteostasis Drive Aging Phenotype in Aplysia californica Sensory Neurons.XLSX by Nicholas S. Kron (9377615)

    Published 2020
    “…The marine mollusk Aplysia californica (Aplysia) is a premier model for the nervous system uniquely suited to investigation of neuronal aging due to uniquely identifiable neurons and molecular techniques available in this model. …”
  6. 121146

    <b>Gene x environment interactions as drivers of lifespan variation in nematodes</b> by Justin Havird (2812975)

    Published 2025
    “…Healthspan (measured as worm activity) generally decreased with age, but in different ways for different genetic strains. …”
  7. 121147

    DataSheet_1_Increased PD-1+Foxp3+ γδ T cells associate with poor overall survival for patients with acute myeloid leukemia.pdf by Jiamian Zheng (12067958)

    Published 2022
    “…</p>Results<p>We found that PD-1 gene was positively correlated with FOXP3 gene and highly co-expressed PD-1 and FOXP3 genes were associated with poor overall survival (OS) from TCGA database. Then, we detected a skewed distribution of γδ T cells with increased Vδ1 and decreased Vδ2 T cell subsets in AML. …”
  8. 121148
  9. 121149

    Table3_Association between OPG polymorphisms and osteoporosis risk: An updated meta-analysis.docx by Xu Han (141301)

    Published 2022
    “…At the same time, the OPG G1181C polymorphism reduces the risk of osteoporosis (C vs G: OR = 0.84, 95% CI = 0.74–0.95; CC vs GG: OR = 0.75, 95% CI = 0.60–0.93; GC + CC vs GG: OR = 0.80, 95% CI = 0.67–0.95; CC vs GG + GC: OR = 0.84, 95% CI = 0.70–1.00). Moreover, a significantly decreased risk of osteoporosis was also discovered in Asian (C vs G: OR = 0.80, 95% CI = 0.66–0.98; CC vs GG: OR = 0.67, 95% CI = 0.47–0.95; GC + CC vs GG: OR = 0.74, 95% CI = 0.58–0.95) and the female (C vs G: OR = 0.85, 95% CI = 0.75–0.97; CC vs GG: OR = 0.77, 95% CI = 0.61–0.96; GC + CC vs GG: OR = 0.79, 95% CI = 0.66–0.95). …”
  10. 121150
  11. 121151
  12. 121152

    Table1_Association between OPG polymorphisms and osteoporosis risk: An updated meta-analysis.docx by Xu Han (141301)

    Published 2022
    “…At the same time, the OPG G1181C polymorphism reduces the risk of osteoporosis (C vs G: OR = 0.84, 95% CI = 0.74–0.95; CC vs GG: OR = 0.75, 95% CI = 0.60–0.93; GC + CC vs GG: OR = 0.80, 95% CI = 0.67–0.95; CC vs GG + GC: OR = 0.84, 95% CI = 0.70–1.00). Moreover, a significantly decreased risk of osteoporosis was also discovered in Asian (C vs G: OR = 0.80, 95% CI = 0.66–0.98; CC vs GG: OR = 0.67, 95% CI = 0.47–0.95; GC + CC vs GG: OR = 0.74, 95% CI = 0.58–0.95) and the female (C vs G: OR = 0.85, 95% CI = 0.75–0.97; CC vs GG: OR = 0.77, 95% CI = 0.61–0.96; GC + CC vs GG: OR = 0.79, 95% CI = 0.66–0.95). …”
  13. 121153

    Table2_Association between OPG polymorphisms and osteoporosis risk: An updated meta-analysis.docx by Xu Han (141301)

    Published 2022
    “…At the same time, the OPG G1181C polymorphism reduces the risk of osteoporosis (C vs G: OR = 0.84, 95% CI = 0.74–0.95; CC vs GG: OR = 0.75, 95% CI = 0.60–0.93; GC + CC vs GG: OR = 0.80, 95% CI = 0.67–0.95; CC vs GG + GC: OR = 0.84, 95% CI = 0.70–1.00). Moreover, a significantly decreased risk of osteoporosis was also discovered in Asian (C vs G: OR = 0.80, 95% CI = 0.66–0.98; CC vs GG: OR = 0.67, 95% CI = 0.47–0.95; GC + CC vs GG: OR = 0.74, 95% CI = 0.58–0.95) and the female (C vs G: OR = 0.85, 95% CI = 0.75–0.97; CC vs GG: OR = 0.77, 95% CI = 0.61–0.96; GC + CC vs GG: OR = 0.79, 95% CI = 0.66–0.95). …”
  14. 121154

    Table4_Association between OPG polymorphisms and osteoporosis risk: An updated meta-analysis.docx by Xu Han (141301)

    Published 2022
    “…At the same time, the OPG G1181C polymorphism reduces the risk of osteoporosis (C vs G: OR = 0.84, 95% CI = 0.74–0.95; CC vs GG: OR = 0.75, 95% CI = 0.60–0.93; GC + CC vs GG: OR = 0.80, 95% CI = 0.67–0.95; CC vs GG + GC: OR = 0.84, 95% CI = 0.70–1.00). Moreover, a significantly decreased risk of osteoporosis was also discovered in Asian (C vs G: OR = 0.80, 95% CI = 0.66–0.98; CC vs GG: OR = 0.67, 95% CI = 0.47–0.95; GC + CC vs GG: OR = 0.74, 95% CI = 0.58–0.95) and the female (C vs G: OR = 0.85, 95% CI = 0.75–0.97; CC vs GG: OR = 0.77, 95% CI = 0.61–0.96; GC + CC vs GG: OR = 0.79, 95% CI = 0.66–0.95). …”
  15. 121155

    CDDO-Me (3 mg/kg) does not affect the body weight, fat mass or blood lipid profile of any group. by Kazuma Ogiso (11993634)

    Published 2022
    “…<p>A: Body weight over the duration of feeding and administration. …”
  16. 121156

    Downregulation of Bak confers resistance of MDA-MB-231 cells to Taxol. by Yanwei Luo (800463)

    Published 2015
    “…<p>(A) QPCR detection of Bak mRNA after siRNA transfection. …”
  17. 121157
  18. 121158

    Proinflammatory cytokines in the liver. by Hyunseong Kim (670519)

    Published 2014
    “…<p>The proinflammatory cytokines and NO in the liver tissue from normal and CD25-depleted mice were measured by ELISA and the Griess method, respectively. The hepatic TNF (A), IL-6 (B) and NO levels (C) were decreased in the PLA2-treated group (APAP + PLA2) compared with the PBS-treated group (APAP). …”
  19. 121159

    Regulation of MMP9 in human hippocampus with cocaine exposure. by Deborah C. Mash (81518)

    Published 2007
    “…Levels of MMP2 activity were unchanged. Data are means±SEM. **<i>p</i> = 0.01 (one-tailed t-test).…”
  20. 121160

    Luteolin reduces LDH release and I/R induced arrhythmia in diabetic rats. by Dongdong Sun (114062)

    Published 2013
    “…The PI3K inhibitor wortmannin pretreatment statistically increased the release of LDH compared with the Luteolin group (a). Luteolin decreased the incidence of PVB, VT and VF attacks as compared with the I/R group. …”